Sharda Cropchem Q4 FY26: Massive PAT Surge and Europe Dominance Drive a Provocative 124% Annual Profit Growth
Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.
At a Glance
The financial performance of Sharda Cropchem in FY26 is nothing short of a statistical outlier in a sector often plagued by inventory overhangs and pricing volatility. If you are looking for a story of capital efficiency and geographic dominance, this is it. The company has reported a staggering 124% growth in annual Net Profit, jumping from ₹304 cr in FY25 to ₹681 cr in FY26.
This isn’t just a marginal improvement; it is a structural breakout. Investors are taking notice of the company’s ability to squeeze out massive margins, with Gross Margins expanding to 35.9% and EBITDA margins hitting 19.7%. The sheer scale of the profit surge—achieving the highest-ever annual PAT in the company’s history—signals a high-conviction recovery in global agrochemical demand.
However, the “detective” in any serious analyst must look at the concentration of this success. A massive 63% of Agrochemical revenue is now tied to Europe. While Europe is currently a gold mine with 43% gross margins, any regulatory tightening or climatic shift in that single continent could send these numbers into a tailspin.
Furthermore, the company is burning cash on intangible assets at an aggressive rate. Capital Expenditure for FY26 stood at ₹505 cr, primarily directed toward the “registration engine.” While this creates a moat, it also means the company is perpetually on a treadmill of spending to keep its portfolio relevant. The balance sheet is rock solid with zero debt, but the high dependency on Chinese sourcing (despite having multiple manufacturers) remains a silent geopolitical risk that no amount of profit can fully hedge.
Is this the peak of a cycle, or is Sharda’s asset-light model finally hitting a sustainable overdrive?
Introduction
Sharda Cropchem operates on a business philosophy that sounds like a financier’s dream: Own the intellectual property, outsource the sweat. The company doesn’t bother with the heavy lifting of manufacturing plants or the biological risks of deep R&D. Instead, it focuses on identifying generic molecules, securing registrations, and managing a global distribution network.
In FY26, the company successfully scaled its operations to ₹5,268 cr in Sales, representing a 22% YoY growth. This growth was primarily volume-driven, showing that the company isn’t just riding a pricing wave but is actually gaining market share in critical territories like Europe and LATAM.
The latest quarter (Q4 FY26) alone contributed ₹2,065 cr to the topline, a 13% increase over the previous year’s Q4. What is truly remarkable is the profit conversion; while revenue grew 13% in the quarter, Net Profit surged by 57% to ₹319 cr. This disproportionate growth in profit versus revenue suggests a significant improvement in the product mix and operational leverage.
The management has been vocal about their “Factory to Farmer” approach, aiming to become a one-stop solution provider. With over 3,011 registrations already in the bag and another 1,004 in the pipeline, the company is effectively building a legal and regulatory fortress around its product portfolio.
To put it bluntly, Sharda Cropchem is a global middleman with a law degree. They don’t make the chemicals; they own the right to sell them.
The company identifies generic molecules (pesticides, herbicides, fungicides) that are going off-patent. They then prepare “dossiers”—massive technical documents—to prove to regulators in countries like Germany or the USA that their version is safe and effective. Once they get the Registration, they have a license to print money in that jurisdiction.
Asset-Light: They outsource 100% of the manufacturing to third parties, mostly in China. This keeps their Balance Sheet clean of “dirty” factory assets and depreciation.
Segment Split: Agrochemicals make up 90% of the revenue, while the rest comes from Non-Agro products like conveyor belts and dyes.
The Moat: You can’t just buy a pesticide in China and sell it in France. You need a registration. Sharda’s moat is its library of 3,000+ registrations. It takes 1 to 7 years to get one, making it a nightmare for new competitors to enter.
They essentially arbitrage the low cost of Chinese manufacturing against the high-value regulated markets of Europe and North America. It’s a genius play, provided the regulators don’t change the rules mid-game.
Financials Overview
The numbers for Q4 FY26 reflect a company firing on all cylinders. The recovery in the agrochemical cycle is evident in the YoY jump in profitability.
Quarterly Performance Comparison (Consolidated)
Metrics
Q4 FY26 (Latest)
Q4 FY25 (YoY)
Q3 FY26 (QoQ)
YoY Change
Revenue
₹2,065 cr
₹1,829 cr
₹1,289 cr
+12.9%
EBITDA
₹513 cr
₹293 cr
₹246 cr
+75.1%
PAT
₹319 cr
₹204 cr
₹145 cr
+56.4%
EPS (Quarterly)
₹35.32
₹22.57
₹16.09
+56.5%
Annualised EPS Calculation:
Since Q4 is the final quarter, we use the full-year reported EPS for valuation purposes.
FY26 Full Year EPS: ₹75.47
Author’s Note: Management walked the talk on margins. In the Feb 2026 concall, they hinted at an EBITDA margin range of 18-20%. They delivered 19.7% for the full year. They promised volume recovery, and Agrochemical volumes grew 13.3% annually. This is a rare instance where the management’s internal GPS actually matched the road.
er is the Dividend. The board just recommended a final dividend of ₹9 per share. Combine this with the interim dividend, and you have a management that is literally flushing shareholders with cash because they have no debt to pay and they refuse to do expensive M&A.
Also, watch the Europe Pipeline. They secured 12 new approvals in Europe recently. Every new approval is basically a new revenue stream with a 43% gross margin. It’s like adding a new floor to a skyscraper that’s already the tallest in the city.
Balance Sheet
The Balance Sheet is a fortress. With Zero Debt, Sharda is in a position to outlast any industry downturn.
Latest Consolidated Balance Sheet (As of March 31, 2026)
